Proapoptotic effect of endocannabinoids in prostate cancer cells.

Authors: O. Orellana-Serradell, C. E. Poblete, C. Sanchez, E. A. Castellón, I. Gallegos, et al
Oncology Reports, April 2015

In the early stages, prostate cancer is androgen‑ dependent; therefore, medical castration has shown significant results during the initial stages of this pathology. Despite this early effect, advanced prostate cancer is resilient to such treatment. Recent evidence shows that…

The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications.

Authors: Juan A. Ramos, Fernando J. Bianco
Indian Journal of Urology, January 2012

Prostate cancer is a global public health problem, and it is the most common cancer in American men and the second cause for cancer-related death. Experimental evidence shows that prostate tissue possesses cannabinoid receptors and their stimulation results in anti-androgenic…

Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.

Authors: N. Olea-Herrero, D. Vara, S. Malagarie-Cazenave, I. Díaz-Laviada
British Journal of Cancer, 15 September 2009

BACKGROUND: We have previously shown that cannabinoids induce growth inhibition and apoptosis in prostate cancer PC-3 cells, which express high levels of cannabinoid receptor types 1 and 2 (CB(1) and CB(2)). In this study, we investigated the role of CB(2) receptor in the anti…

Cannabinoids for cancer treatment: progress and promise.

Authors: Sami Sarfaraz, Vaqar M. Adhami, Deeba N. Syed, Farrukh Afaq, Hasan Mukhtar
Cancer Research, 15 January 2008

Cannabinoids are a class of pharmacologic compounds that offer potential applications as antitumor drugs, based on the ability of some members of this class to limit inflammation, cell proliferation, and cell survival. In particular, emerging evidence suggests that agonists of…